Results 91 to 100 of about 5,855,418 (301)

Longitudinal ovarian response after unilateral oophorectomy.

open access: yes, 2014
Individual changes in ovarian response with age in women with two intact ovaries (a) and after unilateral oophorectomy (d). Ovarian response change/year in women with intact ovaries (b, c), and after unilateral oophorectomy (e, f).
Tom G. Tanbo (643626)   +3 more
core   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim   +17 more
wiley   +1 more source

Investigating the impact of NHS based ovarian cancer screening [PDF]

open access: yes, 2010
the UK ovarian cancer is the fifth most common cancer in females and after uterine cancer, the second most common gynaecological cancer. There were 6,596 new cases diagnosed in the UK in 2006.
Nicholson, S. M.
core   +3 more sources

Ovarian response after unilateral oophorectomy.

open access: yes, 2014
Two-piece exponential decay model of ovarian response in women with intact ovaries (a), in women who had undergone unilateral oophorectomy according to age (b), and time since oophorectomy (c).
Tom G. Tanbo (643626)   +3 more
core   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

open access: yesMolecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David   +12 more
wiley   +1 more source

Efficacy of follitropin delta in potential low responders: a pooled analysis of individual patient data from five randomized controlled trials

open access: yesFrontiers in Endocrinology
ObjectivesThis study evaluated the efficacy of individualized follitropin delta dosing in patients with potential low response, defined by anti-Müllerian hormone (AMH) level <9 pmol/L, undergoing ovarian stimulation for assisted reproductive ...
Rita Lobo   +8 more
doaj   +1 more source

USP7 inhibits FOXO1 activity in chronic lymphocytic leukaemia cells enhancing cell survival

open access: yesMolecular Oncology, EarlyView.
CLL cells rely on BCR‐mediated signalling for survival and proliferation in part through suppression of FOXO1. FOXO1 activity is regulated by a plethora of post‐translational modifications including phosphorylation and ubiquitination. We demonstrated that dual inhibition of BCR signalling and the deubiquitinase USP7 activates FOXO1, modulating its ...
Hassan N.B. Almuhanna   +8 more
wiley   +1 more source

A study of the predictive value of morphometric assessments in clinical outcome in ovarian epithelial malignancy [PDF]

open access: yes
Quantitative pathology as a tool in gynaecological pathology is fairly new. Such techniques allow greater objectivity than histological grading, typing, and residual tumour estimation.
Palmer, Julia Elizabeth
core  

Tumour‐proximal deep serum proteomics identifies biomarkers associated with ovarian cancer

open access: yesMolecular Oncology, EarlyView.
New biomarkers are needed for early ovarian cancer detection. Ovarian (tumour‐proximal) and peripheral vein serum from healthy women and patients with benign or malignant tumours underwent nanoparticle‐enriched deep proteomics. Ovarian serum yielded more protein identifications and revealed tumour‐reflective signatures.
Darren Lau   +9 more
wiley   +1 more source

Prospective study of symptoms of ovarian cancer in postmenopausal women [PDF]

open access: yes, 2010
Background: Research has identified key symptoms of ovarian cancer, although there are gaps in the knowledge about the pattern of symptom onset, severity and frequency. Previous studies are limited by use of non-validated questionnaires, recall bias and
Allen, P.L.
core  

Home - About - Disclaimer - Privacy